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Recent Approach in Microbial 
Pathogen Complications in 
Patients with Cystic Fibrosis
Salah Abdelbary
Abstract
Cystic fibrosis (CF) is a multisystem genetic disease caused by mutations in 
the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Microbial 
infection is the defined characteristics of cystic fibrosis airway disease. This infec-
tion is caused by bacteria, fungi, and viruses which increase complications leading 
to patient death. Additionally, bacterial pathogens including Haemophilus influenza, 
Staphylococcus aureus, Pseudomonas aeruginosa, nontuberculous mycobacterium 
(NTM) species, and MRSA are attributed to pulmonary infections. Subsequently, 
fungal pathogens such as Candida sp. and filamentous fungi such as Aspergillus 
fumigatus can also lead to pulmonary infections. On the other hand, Pseudomonas 
aeruginosa is the most common bacterial pathogen leading to complications in 
CF distal airways disease. Also, Aspergillus fumigatus can lead to aspergillus lung 
diseases including allergic bronchopulmonary aspergillosis and aspergilloma for-
mation. Control of pathogenic microorganisms associated with cystic fibrosis may 
prevent pulmonary complications and has the potential to improve the prognosis of 
this life-limiting disease.
Keywords: cystic fibrosis, Pseudomonas aeruginosa, Aspergillus fumigatus, 
Haemophilus influenzae, MRSA, CFTR, NTM, microbial infection, respiratory 
diseases
1. Introduction
Cystic fibrosis (CF) is an autosomal recessive disease which basis on a dys-
functional cystic fibrosis transmembrane conductance regulator (CFTR) protein 
[1]. It is an inherited chronic disease that remains a common cause of morbidity 
and mortality in affected patients [2]. Also, it is a monogenic autosomal recessive 
condition affecting approximately 1 in 3000 of the Caucasian population and 
involves multiple organs, predominantly the lungs, gastrointestinal tract, pancreas, 
and liver [3].
Mutations in CFTR gene are resulted in defective mucociliary clearance leading 
to the production of thick and sticky bronchial mucus. This mucus facilitates the 
entrapment of viruses, bacteria, and fungal spores and acts as a suitable environ-
ment for growth of these microorganisms [4]. High morbidity and mortality rates 
are secondary to recurrent respiratory infections, which, when associated with 
this obstructive lung disease, lead to respiratory insufficiency [5]. Complex micro-
organisms and microbial communities can be identified in the distal airways in a 
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variety of respiratory diseases, including CF [6]. Chronic infection is the defined 
characteristics of CF airway disease. Conditions within the airways of patients 
living with CF are conducive to colonization by a variety of opportunistic bacterial, 
viral, and fungal pathogens [7].
Also, bacterial strains that colonize the respiratory tract include Haemophilus 
influenzae, Staphylococcus aureus, Pseudomonas aeruginosa [8], and Burkholderia 
cepacia; these have been recorded as the main common CF pathogens. Traditionally, 
Pseudomonas aeruginosa has been regarded as the main pathogen in CF, and chronic 
infections have been linked to disease morbidity and mortality [9]. Little attention 
has been paid to the role of Aspergillus sp. and other filamentous fungi in CF. It has 
become more apparent, however, that Aspergillus sp. may play an important role in 
chronic lung disease in CF [10]. This chapter discusses the complications of micro-
organisms in patients with cystic fibrosis, including bacterial, fungal, and viral 
pathogens and their effects on this disease leading to an increased risk of mortality.
2. Defining causes and history of cystic fibrosis
Cystic fibrosis is a multisystem genetic disease that affects children and young 
adults [11]. It is caused by mutations in CFTR gene leading to defective or insuf-
ficient amounts of functional CFTR protein and causes abnormalities in chloride 
(Cl), bicarbonate (HCO3), and sodium (Na) transport across cell membranes with 
serious consequences on multiple organs. The CF lung disease is characterized by 
infection and inflammation with eventual bronchiectasis and eventual respiratory 
failure causing death in over 90% of CF patients [3].
Cystic fibrosis is an autosomal recessively inherited disorder caused by the pres-
ence of one of more than 1500 possible mutations in CFTR gene with an occurrence 
of the clinical disease being 1 in 2500 live births. This mutation leads to the non-
function or loss of function of CFTR (a cyclic AMP-regulated chloride ion channel) 
leading to defective chloride ion transport through epithelial cell surfaces [12].
Since its first description in 1938, study of the genetics, pathophysiology, and 
clinical manifestation of the disease has led to the creation of new therapies and 
significantly improved quality of life and survival [2].
In CF, the biology and treatment strategies are important to understand for 
several reasons. Firstly, it is the most common cause of chronic respiratory failure 
in children and adults. Secondly, CF is a common reason for the dysfunction of 
pancreatic exocrine in children and adults. Thirdly, the majority also develop pan-
sinusitis. Other potential consequences of CF include diabetes, liver disease, bone 
disease, and infertility [3].
Advances in research of CF have given a roadmap for the understanding of 
pathophysiology studies and treatment stages for other severe airway diseases, 
including chronic obstructive pulmonary disease, non-CF bronchiectasis, and 
asthma [11].
Survival of individuals with CF has improved significantly over the last half 
century from a median age of survival of 5 years in the 1970s to 40 years of age as 
of 2011. There are different reasons for improvement in clinical outcomes includ-
ing the intense use of antibiotic therapy, advancement in chest physiotherapy, 
nutritional support, specialized CF units, and introduction of CFTR modulators; 
however, the majority of CF deaths still occurred in young adult especially in the 
ages between 21 and 30 years as a consequence of respiratory failure [13]. Recent 
research also suggests that even asymptomatic genetic carriers for CF may be at risk 
for subclinical physiological derangements, which can be exacerbated by external 
stresses and other environmental triggers [14, 15].
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3. Microbial complications in patients with cystic fibrosis
Airways of patients with CF are usually infected with various microorganisms. 
In infected airways of CF patients, microhabitats can develop owing to local differ-
ences in the inflammatory reaction between the different focal areas of infection 
and also as a result of the competing activities of the many co-colonizing microbial 
populations [16]. Several bacterial strains are major causes of mortality and mor-
bidity and have therefore been studied intensely [12].
3.1 Microbial infection in patients with cystic fibrosis
Chronic infection is a characteristic of CF airway disease. So, conditions in the 
airways of patients with CF are conducive to forming colonization by different 
microorganisms such as bacterial, fungal, and viral pathogens. Molecular identifi-
cation of microorganisms has emphasized and recorded the polymicrobial nature of 
microbial infections in the CF airway microenvironment. Additionally, changes in 
airway of CF physiology through the loss of CFTR functionality lead to a variety of 
immune dysfunctions that permit microbial pathogen colonization and microbial 
persistence [7].
The prognosis of patients with the hereditary disease CF is substantially 
dependent on chronic respiratory infection and inflammation [17]. CF lungs are 
often colonized or infected with a complex microbial species, mainly composed of 
bacteria, provoking acute and chronic infections [18]. Airway infection accounts for 
90% of the morbidity and mortality observed in CF patients. These chronic infec-
tions are typically associated with a few bacterial pathogens such as Pseudomonas 
aeruginosa, Staphylococcus aureus, and Burkholderia cepacia complex [19].
High morbidity and mortality rates in cystic fibrosis patients are secondary 
to recurrent respiratory infections, which, when associated with this obstructive 
lung disease, lead to respiratory insufficiency, the main cause of death in these 
patients [5, 14].
CF lung disease is characterized by progressive colonization of respiratory tract 
infection by different bacterial strains leading to polymicrobial biofilms. Also, 
the emergence of nontuberculous mycobacteria (NTM) infections has caused 
additional challenges to patient management due to their multiresistance nature to 
antibiotics [20]. These are compounded by the impairment of mucociliary clear-
ance and the inability to mobilize thick secretions within the airways. These result 
in mucus impaction, microorganism colonization, recurrent infections, persistent 
inflammation and death from respiratory failure. With improvement in CF progno-
sis, new challenges emerge, including the management of fungal colonization and 
infection [1].
3.2 Host-microbe interactions with CF lung infection
Bacterial and fungal infections are hallmarks of CF lung disease. In the era of 
long-term inhaled antibiotics and increasing CF patient survival, new “emerging” 
pathogens are detected in CF airways, yet their pathophysiological impact remains 
largely controversial and incompletely defined. As a consequence to chronic 
microbial triggers, innate immune cells, particularly neutrophils, are continuously 
recruited into CF airways where they combat pathogens but also lead to tissue 
injury through the release of oxidants and proteases. The coordinated interplay 
between host immune cell activation and pathogens is essential for the outcome 
of CF lung disease. A better understanding of this phenomena may enhance the 
survival in CF [21–23].
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3.3 Nontuberculous mycobacteria species in patient with cystic fibrosis
NTM are wide environmental microorganisms causing chronic pulmonary 
infection in lung diseases such as CF. Also, pulmonary disease caused by NTM has 
a major threat with CF and difficult to diagnose and problematic to treat according 
to the US Cystic Fibrosis Foundation (CFF) and European Cystic Fibrosis Society 
(ECFS). Additionally, the most common NTM species identified in CF are the 
slow-growing Mycobacterium avium complex (MAC) including M. intracellulare, 
M. avium, and M. chimaera and the rapid-growing M. abscessus complex (MABSC) 
including subspecies of M. a. abscessus, M. a. massiliense, and M. a. bolletii. Other 
less common NTM species include M. kansasii, M. simiae, and M. fortuitum [24].
In addition, there are more than 100 types of NTM, and more are being found 
every year. The reported prevalence of NTM in CF varies widely from 45 to 40% 
with Mycobacterium avium complex and Mycobacterium abscessus complex being the 
most common [25, 26].
4. Airway colonization process in patients with cystic fibrosis
Colonization of microorganisms in respiratory tract infection within young CF 
patient includes common pathogens such as S. aureus or H. influenza then succeeded 
by P. aeruginosa infection in the latter stages of CF.
It is well established that Pseudomonas aeruginosa is a frequent and virulent 
pulmonary pathogen in patients with CF [27]. After a period of intermittent coloni-
zation, the organism becomes permanently established and is difficult to eradicate. 
Most patients with CF become chronically infected with wild-type P. aeruginosa 
strains in early childhood [28]; prevalence increases with age, so that as many as 
80% of patients with CF are infected by the time they reach 20 years [27]. During 
the years following initial colonization, the wild-type strains uniformly mutate into 
mucoid variants [28]. Conversion to the mucoid phenotype is thought to be driven 
by the unique CF microenvironment [29–31]. For patients with CF, this conversion 
results in a significant increase in morbidity and mortality accompanied by a mea-
surable decline in pulmonary function [28]. The mucoid matrix is believed to allow 
the formation of protected biofilm microcolonies [30, 32] and provide increased 
resistance to opsonization, phagocytosis, and digestion [33]. Furthermore, resis-
tance to various antibiotics is increased [27, 34].
The potentiality of pathogenic bacterial colony morphotypes in P. aeruginosa 
evolved to a non-swimming phenotype form. So, motility is considered as one of 
the first steps of P. aeruginosa in CF lungs that lead to adaptation steps including 
biofilm formation and progress to chronic infection. Also, impaired swimming 
motility seemed to be a candidate to disease marker of P. aeruginosa infection 
development. So far, the pathological changes in the lungs are best studied due to 
the high mortality rates linked to poorer lung function and recurrent development 
of infections [18].
Also, the lungs of people with cystic fibrosis are predominantly colonized with 
Pseudomonas aeruginosa using the following mechanism: firstly, reduced mucocili-
ary clearance combined with the malfunction of antibacterial peptides; secondly, 
impaired defense of the lungs due to low levels of glutathione and nitrous oxide; 
thirdly, reduced ingestion of bacteria by lung cells; and finally, increased numbers 
of bacterial receptors [35].
On the other hand, earlier age of infection with P. aeruginosa in our population 
was strongly associated with greater likelihood of severe lung disease later in life, 
most particularly in those subjects who acquired P. aeruginosa before the age 5; the 
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observed association was stronger in females than in males. P. aeruginosa infection 
may be a cause of more severe CF lung disease but may also be a marker of some 
other processes determining lung function in children with CF [36].
5. Fungal infection in patients with cystic fibrosis
Fungi are generally divided into molds or yeasts with the latter circumferentially 
shaped with a one-celled thallus. Molds also known as filamentous fungi grow 
as branching cylindrical hyphae [1]. Aspergillosis is the most well-characterized 
and well-recognized Aspergillus disease in CF, but reported prevalence varies 
significantly and is likely to be underdiagnosed. Aspergilli are saprophytic, spore-
forming, filamentous fungi found ubiquitously in the environment. A. fumigatus is 
the most prevalent species causing human disease and is the species most frequently 
isolated from the respiratory secretions of CF patients [37].
Yet, the relative contribution of other emerging pathogens, such as S. maltophilia, 
Aspergillus, Candida, and Scedosporium species, remains less precisely defined. 
Aspergillus fumigatus is the only species that is associated with an increased risk for 
infection with P. aeruginosa [9]. Candida sp. is found in as many as 70% of patients 
with CF. The clinical significance of Candida in patients with CF is not clearly under-
stood, but most clinicians discount these organisms as not significant [38]. Fungemia 
caused by Trichosporon has been reported in two patients with CF, who were double 
lung transplant recipients [39]. Some species such as Exophiala dermatitidis grow as 
unicellular fungi (yeast) at human body temperature but in the case of filamentous 
fungi at room temperature. Trichosporon species as of any Candida species may 
produce true mycelium in culture conditions or in host tissues. So, there are varia-
tions in isolation and purification of yeast and filamentous fungi. Additionally, some 
fungal strains are thermotolerant filamentous mycota such as Aspergillus fumigatus 
which are the most common, and others include Scedosporium species and E. derma-
titidis [1]. A. fumigatus is frequently detected in respiratory secretions of both adults 
and children with CF. Once present in the airways, Aspergillus can exacerbate lung 
inflammation, establish infection, and trigger hypersensitivity responses [10].
In patients with CF, complications increased when exposed to A. fumigatus 
spores causing impaired mucociliary clearance and defective innate immune 
responses leading to accumulation and persistence of fungal spores within the 
smaller airways. Also, germination of spores leads to the formation of fungal 
hyphae and release of antigens, phospholipases, proteases, and other virulence fac-
tors which damage the airway of epithelial cells and allow a large dose of antigenic 
factors access to the interstitial and vascular compartments [40].
Also, exotic genera can be found in CF airway secretions, such as Penicillium, 
Alternaria, or Scedosporium. Some studies provide the first evidence that even 
healthy airways are not sterile and contain distinct fungi called “pulmonary myco-
biome.” The kinetics, dynamics, and disease relevance of the pulmonary myco-
biome, however, are poorly understood [7]. The majority of yeasts in CF belong 
to Candida species and the most common species such as Candida albicans and 
other yeast strains recorded such as Candida parapsilosis, Candida krusei, Candida 
glabrata, and Candida dubliniensis [1].
6. Viral infection in patients with cystic fibrosis
Progression of CF respiratory disease is influenced by viral infection. 
Respiratory viral infections include respiratory syncytial virus (RSV), rhinovirus, 
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influenza, para influenza, and adenovirus which is RSV and influenza infection 
leading to decreases in lung function [41]. Also, viral respiratory infections show 
pronounced and long-lasting effects on patients with CF, resulting in significant 
declines in forced vital capacity (FVC), forced expiratory volume in 1 second  
(FEV-1), and significant increases of both the frequency and duration of hospi-
talizations especially that the frequency of viral respiratory infections is closely 
associated with pulmonary deterioration in patients with CF [42]. Additionally, 
viral respiratory infections occur in equal frequency in CF patients and healthy 
controls which in CF patients viral upper respiratory tract infections are associated 
with lower respiratory tract symptoms in 31–76%. Viral infections cause long-term 
respiratory morbidity in CF patients [43].
7. Prevention and control of microorganisms in cystic fibrosis
Despite the development of antibiotics and vaccines, patients with CF are still 
faced with many debilitating and fatal infections, which demonstrate the adapt-
ability of microbial pathogens [44]. The choice of antibiotic depends on in vitro 
sensitivity patterns. Physicians treating patients with CF are increasingly faced with 
infection with multidrug-resistant strains of Pseudomonas aeruginosa. Also, innately 
resistant organisms such as Burkholderia cepacia, Stenotrophomonas maltophilia, and 
Achromobacter xylosoxidans become more prevalent [45].
Additionally, many studies resulted in strong indicator for a relevant importance 
of mutators in bacterial populations especially in infectious diseases. High preva-
lence and mutators are recorded environmentally in chronic respiratory infection 
with Pseudomonas aeruginosa in CF patients [46].
7.1 Strategies and guidelines for bacterial infection control within CF patients
Guidelines on infection control developed for general patient populations are 
applicable to CF patients. Historically, before 1998, guidelines on infection control 
were applied to acute-care hospitals. Recently it includes for non-acute-care set-
tings. Also, it has shifted from hospitals to home and outpatient clinics to reduce 
days of hospitalization and provide chronic suppressive treatments. Infection con-
trol in CF guidelines has been developed by Healthcare Infection Control Practices 
Advisory Committee (HICPAC) and Centers for Disease Control and Prevention 
(CDC) [47].
Common pathogens that infect the lungs of CF patients include Staphylococcus 
aureus, Haemophilus influenzae, Pseudomonas aeruginosa, and Burkholderia cepacia. 
Aggressively treating pulmonary infection with antibiotics has contributed to 
improved survival in patients with CF but has also promoted multiple drug-resis-
tant bacteria [48].
Antibiotic therapy leads to improvement in lung function, the best predictor of 
survival in CF patients which treat CF lung disease morbidity based on decisions 
with which antibiotics are selected according to broad empirical and based on the 
severity of the patient’s pulmonary exacerbation, the colonizing microorganisms, 
and the patient’s age [49].
A range of anaerobic bacterial species are present in huge numbers in the lungs 
of CF patients, which contribute significantly to infection and inflammation in the 
CF lung. So, informed alterations of antibiotic treatment to target anaerobes is done, 
in addition to the primary infecting pathogens, may improve management [50].
A positive approach to the protection of the lung from early in life seems to be 
the only way to change the slope of the survival curves [51]. Ticarcillin can be used 
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in the treatment of pulmonary exacerbations of cystic fibrosis due to susceptible 
strains of Pseudomonas aeruginosa [52, 53].
Also, Alcaligenes bacterial strains are characterized as motile, Gram-negative, 
producing oxidase enzyme. The most common is Alcaligenes xylosoxidans known as 
Achromobacter xylosoxidans. The bacterial genus is composed of three main species 
such as Achromobacter piechaudii, Achromobacter xylosoxidans, and Achromobacter 
faecalis. These bacterial strains observed multiple antibiotic resistance especially 
grouped of aminoglycosides and recorded sensitivity to cephalosporins (third 
generation) [54].
7.2 Inhalational antibiotics for the treatment of Pseudomonas aeruginosa
In recent years, there are emergences of inhaled antibiotics to treat patients with 
Gram-negative bacterial infection such as P. aeruginosa infection. The benefits of 
which are explained below [55, 56].
Inhaled tobramycin, inhaled colistin, and inhaled aztreonam are used to control 
chronic P. aeruginosa infections in patients with CF [57]. In CF, tobramycin inhala-
tion solution contributed to improved survival and reduced lung function decline 
[58]. Subsequently, the development of antibiotic agents can achieve high tissue 
concentrations to control bacterial infection that is difficult to treat in hosts [59]. 
Inhaled tobramycin achieves a sputum concentration of drug at least 25 times the 
MIC, with a median serum/sputum concentration of 0.01. Such high concentrations 
are required for the effective killing of P. aeruginosa because aminoglycosides bind 
to mucins in sputum and reduce the availability of effective antibiotic. Also, early 
randomized, double-blind, placebo-controlled trials conducted in patients with CF 
were short-term but demonstrated positive results with the use of aztreonam solu-
tion for inhalation compared to placebo. Colistin is bactericidal and active against 
Gram-negative bacteria including P. aeruginosa. Nebulized colistin is a preferred 
inhaled therapy for patients with CF and chronic P. aeruginosa [59]. Inhaled levo-
floxacin was studied in patients with CF and P. aeruginosa lung infection. Also, 
nebulized levofloxacin solution (MP-376) is a novel therapy that is currently being 
evaluated in phase I, II, and III clinical trials among patients with stable CF and 
recent isolation of Pseudomonas aeruginosa from sputum [60].
7.3 Antifungal therapy to control yeasts and filamentous fungi with CF patients
Antifungal therapy is usually considered when the deteriorating respiratory 
function is not responding to antibacterial therapy and A. fumigatus is growing and 
identified in sputum cultures [61]. Long-term antifungal treatment with mold active 
azoles, the only class of antifungals with an oral formulation, is not without risk of 
toxicity and adverse events and should be carefully balanced against its benefit [10].
A. fumigatus can grow in sputum cultures, and antifungal therapy is not effective 
[61]. Also, Scedosporium sp. is the second most frequent cystic fibrosis associated 
filamentous fungi which is resistant to many antifungal agents [62].
In CF, Candida albicans causes 95% of all Candida infections, whereas the 
remainder is caused by Candida glabrata, Candida parapsilosis, and Candida krusei. 
Also, Candida dubliniensis has been isolated in CF; however, little is known about its 
potential for virulence, and treatment modality is not clearly defined [63].
7.4 Antiviral therapy to control respiratory viruses with CF patients
Respiratory viruses associated with exacerbations in CF patients and upper 
respiratory symptoms are strong predictors for their presence. Some studies have 
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suggested a role played by respiratory viruses in exacerbation of CF. The impact of 
respiratory viruses is likely to be underestimated due to the low detection rate by 
conventional laboratory methods. Molecular techniques such as multiplex PCR have 
improved their diagnostic accuracy identifying respiratory viruses in CF patients 
which are important in clinical decision-making and are potentially important 
as new antivirals are becoming readily available [64]. A few therapeutic options 
recorded to treat virus-induced CF pulmonary exacerbations include macrolide 
antibiotic (azithromycin). It has antiviral properties of the human bronchial epi-
thelial cells and stimulates antiviral mechanisms in bronchial epithelial cells within 
the CF airway control infection with rhinovirus by reducing rhinovirus replication 
as an interferon pathway [65]. Also, there are exciting prospects such as antiviral 
host defense peptides in development and can be novel therapeutics targeting 
rhinovirus [66].
Additionally, CF patients infected with influenza A(H1N1) showed increased 
case fatality rate (CFR) and morbidity compared to patients with other chronic 
respiratory diseases, so, early antibiotic and antiviral treatment strategies are 
important to control it in CF patients [67].
8. Conclusion
This chapter concludes that complications of microorganisms associated with 
cystic fibrosis disease are very high and can lead to patient death. Pathogenic 
microorganisms isolated from CF patients included Gram-negative bacteria, Gram-
positive bacteria, unicellular fungi, multicellular fungi, and viruses.
The most common Gram-negative bacterial pathogens are Pseudomonas aerugi-
nosa and Haemophilus influenzae. Also, the most common Gram-positive bacterial 
pathogen is Staphylococcus aureus especially MRSA. Other bacterial pathogens 
are isolated from CF patients, such as NTM species, Alcaligenes xylosoxidans, and 
Burkholderia cenocepacia.
In addition, Candida albicans is the most common unicellular fungi, and 
Aspergillus fumigatus is the most common filamentous fungi. Influenza A and B 
viruses are major viruses in causing respiratory exacerbations in CF, and both 
viruses are more commonly detected during pulmonary exacerbations.
To prevent this microbial complication, appropriate antimicrobials can be 
used to treat bacterial infections, antifungal therapy for treating pathogenic fungi 
and antiviral to manage viral infections. With prospects, researchers must work 
to produce new therapeutic options to control multidrug-resistant bacteria and 
resistant fungi and virus. These new treatment options may further enhance the 
prognosis in patients with CF.
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